PIK3CD and acute lymphoblastic leukemia: The administration of BEZ235 to improve glucocorticoid resistance in pediatric T-ALL and the use of PKI-587 to decrease cancer cell proliferation in T-ALL demonstrated that dual PI3K/mTOR inhibitors significantly improved the treatment effect compared with inhibiting mTOR or PI3K alone [158–160].